

Is Qvar RediHaler in shortage in 2026? Get the latest update on availability, pricing, and what you can do if you can't find your asthma inhaler.
If you take Qvar RediHaler for your asthma, you may have noticed something frustrating: your pharmacy can't always fill your prescription when you need it. Maybe you've been told to "try again next week" or "call around." It's a stressful situation — especially for a medication you depend on every single day.
In this article, we break down the current state of Qvar availability in 2026, explain what's behind the supply issues, and give you actionable steps to get your medication.
As of early 2026, Qvar RediHaler (Beclomethasone Dipropionate) is not officially listed on the FDA's drug shortage database. That means there's no formal, nationwide shortage declared by the FDA.
However, that doesn't tell the whole story. Patients across the country have reported intermittent difficulty finding Qvar at their local pharmacies. These pharmacy-level stock-outs can feel like a shortage even when the FDA hasn't formally recognized one. The issue is uneven distribution — some pharmacies have it, others don't.
Several factors contribute to the availability challenges patients face:
Qvar RediHaler is made exclusively by Teva Pharmaceuticals. There is no generic version, and patents don't expire until around May 2031. When a single company is the sole source for a medication, any manufacturing delay or distribution hiccup affects the entire supply.
The pharmaceutical supply chain has been under significant strain in recent years. Raw material sourcing, specialized inhaler device manufacturing, and global logistics challenges all play a role. Inhaler devices are more complex to produce than tablets or capsules, making them more susceptible to disruption.
When brand-name Flovent HFA was discontinued and replaced by an authorized generic, prescribing patterns shifted across the ICS market. Some patients and providers turned to Qvar as an alternative, increasing demand at a time when supply was already tight.
Chain pharmacies stock medications based on demand forecasting. Brand-name-only products like Qvar may be ordered in smaller quantities, leading to more frequent stock-outs at individual locations. Independent pharmacies often have more flexibility in their ordering.
The cash price for Qvar RediHaler in 2026 ranges from approximately $306 to $414 per inhaler (10.6g canister, 120 inhalations), depending on the pharmacy and your location.
With a discount card like GoodRx, you may find prices as low as $264. The Teva Savings Card can reduce copays to as low as $15 per fill for commercially insured patients. For uninsured patients who meet income criteria, Teva's Patient Assistance Program may provide Qvar for free.
For a full breakdown of savings options, see our guide on how to save money on Qvar in 2026.
While Qvar remains a strong choice for asthma maintenance, 2026 offers patients more options than ever in the ICS category:
If you're interested in alternatives, read our full guide on alternatives to Qvar. Always consult your doctor before switching medications.
If you want to stick with Qvar, here are the best ways to find it:
For more detailed strategies, check out our guide on how to find Qvar in stock near you.
The Qvar situation in 2026 isn't a full-blown shortage, but it's not smooth sailing either. Intermittent availability issues mean you need to be proactive about filling your prescription. Use tools like Medfinder, explore savings programs, and keep your doctor in the loop about any access challenges. Your asthma management is too important to leave to chance.
If you're a healthcare provider looking for clinical guidance on Qvar availability, see our provider-focused shortage update.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.